Elicio Therapeutics, Inc. Payments of Debt Issuance Costs
Elicio Therapeutics, Inc. (ELTX) reported Payments of Debt Issuance Costs of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2022-11-14
- Elicio Therapeutics, Inc. payments of debt issuance costs for the quarter ending 2022-09-30 was $0.00.
- Elicio Therapeutics, Inc. payments of debt issuance costs for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. payments of debt issuance costs for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. payments of debt issuance costs for the quarter ending 2021-09-30 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month |
|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.41M derived: sum of 2 quarters · filed 2022-11-14 | $3.07M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $3.07M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $1.67M 10-Q · filed 2022-05-16 | ||
| 2020-09-30 | -$117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 |
| 2020-06-30 | $117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $117.00K 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |